Observational Study on Patients With Hepatocellular Carcinoma (HCC)

July 12, 2019 updated by: Jinlin Hou, Nanfang Hospital of Southern Medical University
This is an ongoing, longitudinal, single centre, observational, retro-prospective clinical cohort study of patients with HCC in usual clinical practice. All the HCC patients diagnosed and treated in Liver Cancer Center, Nanfang Hospital are consecutively collected and followed up.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Anticipated)

3000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Guangdong
      • Guangzhou, Guangdong, China

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients diagnosed and treated as HCC in Liver Cancer Center, Nanfang Hospital

Description

Inclusion Criteria:

  • Clinical diagnosis of HCC;
  • Age ≥ 16 years;
  • Received treatment targeting for HCC at least once, including operation, ablation, TACE, sorafenib, radiotherapy, chemotherapy, etc;
  • Good compliance with clinical treatment.

Exclusion Criteria:

  • Diagnosed as other pathological types such as cholangiocarcinoma, or mixed liver cancer;
  • Received only traditional Chinese medicine or symptomatic supportive treatment; (3) survival time ≤ 7 days;
  • HCC diagnosed after liver transplantation;
  • Poor compliance or important data deficient.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluate the overall survival rate of all HCC patients
Time Frame: 10 years
In order to identify the potential influence factors of HCC patients survival
10 years
Evaluate the recurrence free survival rate of HCC patients after curative treatments
Time Frame: 10 years
In order to identify the potential influence factors of tumor recurrence
10 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Nanfang Hospital of Southern Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2011

Primary Completion (Anticipated)

August 31, 2019

Study Completion (Anticipated)

December 31, 2022

Study Registration Dates

First Submitted

April 23, 2019

First Submitted That Met QC Criteria

July 12, 2019

First Posted (Actual)

July 16, 2019

Study Record Updates

Last Update Posted (Actual)

July 16, 2019

Last Update Submitted That Met QC Criteria

July 12, 2019

Last Verified

July 1, 2019

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NFHCC-01

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hepatocellular Carcinoma

Clinical Trials on No intervention

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Georgia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe